Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5873094 | 0.89 | ADORA2A (0.37) | HCRTR1HCRTR2KDM5APDE10A | |
| SCHEMBL5774120 | 0.88 | KDM5A (0.40) | HCRTR1HCRTR2KDM5AHRH3DYRK1A | |
| SCHEMBL5769407 | 0.87 | DYRK1A (0.35) | HCRTR1HCRTR2KDM5AHRH3DYRK1A | |
| SCHEMBL5873229 | 0.85 | DRD2 (0.35) | HCRTR1HCRTR2KDM5AALDH1A1 | |
| SCHEMBL5770207 | 0.84 | KDM5A (0.41) | KDM5A | |
| SCHEMBL5770403 | 0.84 | PIM1 (0.42) | HCRTR1HCRTR2KDM5ADYRK1AALDH1A1 | |
| SCHEMBL5872958 | 0.84 | MKNK1 (0.43) | HCRTR1HCRTR2KDM5AALDH1A1 | |
| SCHEMBL5873158 | 0.84 | PIM1 (0.39) | HCRTR1HCRTR2KDM5ADYRK1AALDH1A1 | |
| SCHEMBL5873054 | 0.83 | PIM1 (0.40) | HCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL5872866 | 0.82 | KDM5A (0.40) | HCRTR1HCRTR2KDM5ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HCRTR1 4881/4885HCRTR2 4876/4885KDM5A 2543/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | HCRTR1 4881/4885HCRTR2 4876/4885KDM5A 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.